Anti-DR5 antibody [EPR28153-84] is a Rabbit Monoclonal antibody that is used in DR5 Flow Cytometry (Intra), Western Blot. Suitable for Mouse samples.
TARGET: DR5 (TNFRSF10B) is a pro-apoptotic death receptor for the TRAIL protein, which induces cell death. Five TRAIL receptors have been identified, however only two, DR4 and DR5 contain the death domain and have been identified as promising targets for cancer treatment. TRAIL. Mouse DR5 has similar function to human DR4 and DR5, and is studied in mouse tumor models exploring TRAIL therapies and resistance mechanisms.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Flow Cyt (Intra) | WB | ICC/IF | IHC-P | |
---|---|---|---|---|
Mouse | Tested | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/500 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes - |
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.
CD262, Dr5, Killer, Tnfrsf10b, Tumor necrosis factor receptor superfamily member 10B, Death receptor 5, MK
Anti-DR5 antibody [EPR28153-84] is a Rabbit Monoclonal antibody that is used in DR5 Flow Cytometry (Intra), Western Blot. Suitable for Mouse samples.
TARGET: DR5 (TNFRSF10B) is a pro-apoptotic death receptor for the TRAIL protein, which induces cell death. Five TRAIL receptors have been identified, however only two, DR4 and DR5 contain the death domain and have been identified as promising targets for cancer treatment. TRAIL. Mouse DR5 has similar function to human DR4 and DR5, and is studied in mouse tumor models exploring TRAIL therapies and resistance mechanisms.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Unsuitable for mouse tissue.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
DR5 also known as Death Receptor 5 TRAIL-R2 or TNFRSF10B is a protein critical in apoptosis. It is a transmembrane receptor with a mass of approximately 54 kDa. Researchers find it expressed mostly in tissues such as lung colon and prostate. DR5 functions by binding to its ligand TRAIL triggering the extrinsic apoptotic pathway. Through this mechanism DR5 initiates a cascade of caspase activation that leads to cell death.
DR5 plays a significant role in the regulation of apoptosis particularly in cancer cells. It is a component of the TRAIL receptor complex which includes several other death receptors like DR4. This complex formation allows DR5 to mediate apoptotic signals more efficiently. By controlling apoptosis DR5 helps maintain tissue homeostasis and prevents abnormal cell proliferation.
DR5 is an important part of the TRAIL signaling pathway and the extrinsic apoptosis pathway. It connects with proteins like FADD and Caspase-8 essential in the apoptotic signaling cascade. By interacting with these proteins DR5 drives the progression of the apoptotic signal ensuring the removal of dysfunctional cells. Such pathways are vital for restraining tumor development and progression.
DR5 exhibits significant relevance to cancer and autoimmune diseases. Its ability to induce apoptosis through the TRAIL pathway keeps oncogenic transformations in check. In cancer DR5 often interfaces with other proteins like Bcl-2 which are involved in cell survival. Furthermore defects or aberrant expressions in DR5 have associations with autoimmune disorders where excessive cell death or survival contributes to disease pathology. DR5's role in these conditions makes it a promising target in therapeutic strategies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized Neuro-2a (mouse neuroblastoma neuroblast, Left) / NIH/3T3 (mouse embryonic fibroblast, Right) cells labelling DR5 with ab321972 at 1/500 dilution (0.1ug) (Red) compared with a Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody).
Goat Anti-Rabbit IgG (Alexa Fluor® 488, Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed ab150081) at 1/5000 dilution was used as the secondary antibody.
Negative control: Neuro-2a
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Low expression: Neuro-2a
This blot was developed using a high sensitivity ECL substrate.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
All lanes: Western blot - Anti-DR5 antibody [EPR28153-84] (ab321972) at 1/1000 dilution
Lane 1: NIH/3T3 (mouse embryonic fibroblast) transfected with scrambled siRNA control whole cell lysate at 20 µg
Lane 2: NIH/3T3 transfected with siRNA specifically targeting DR5 whole cell lysate at 20 µg
Lane 3: C2C12 (mouse myoblast) whole cell lysate at 20 µg
Lane 4: Neuro-2a (mouse neuroblastoma neuroblast) whole cell lysate at 20 µg
Lane 5: MEF (mouse embryo fibroblast) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Developed using the ECL technique.
Observed band size: 42 kDa, 36 kDa
Exposure time: 103s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com